RMDResMed
Is it growing?
Neither accelerating nor breaking down: nothing decisive, though operating margin widening (+0.7 points).
Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +12% a year.
Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.
Trailing-twelve-month operating margin, 33.4% now against 32.7% a year earlier.
All from SEC EDGAR, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.
Is RMD growing?
ResMed has grown revenue 10% a year over three years and 12% a year over five, with earnings per share compounding at 20%.
Revenue growth, 3-year annual rate · Medical Instruments & Supplies median +9.8% · steady growth, ahead of inflation · compounded from trailing twelve-month revenue
- Revenue growth, 5-year rate
- +12%
Revenue growth, 5-year rate · +10% over three · growth has slowed since the five-year average
- Earnings per share, 3-year rate
- +20%
Earnings per share, 3-year rate · revenue +10% · earnings outgrew revenue: margins or the share count worked for shareholders
- Years of annual history on file
- 18
Years of annual history on file · FY2009 to FY2026, as filed
Details›
- Revenue FY2022
- $3.58B
- Revenue FY2023
- $4.22B
- Revenue FY2024
- $4.69B
- Revenue FY2025
- $5.15B
- Revenue FY2026
- $5.65B
Annual income statements as filed with the SEC.
Medical Instruments & Supplies
The closest names by size in the same industry